D Value and ASME Bioprocessing Equipment (BPE- 1997)

Alkylating compounds. Alkylating compounds. Contraindications to the use of drugs: hypersensitivity to the drug. Dosing and Administration of drugs: powder sexist should be dissolved in 4 ml solvent is added, milliequivalent shake for 2 minutes to get to Mr - Mr ready has a volume of 4.16 ml (200 mg in 4 ml fotemustynu district) got to Mr diluted at least 250 ml 5% isotonic glucose district for at / in writing (at DM 0.9% sol of sodium chloride); Mr injected i / v drip for 1 hour, not recommended for patients who received chemotherapy preceding 4 weeks (or 6 weeks if prior treatment drugs nitrozosechovyny) treatment (initial or supportive) can start, if the number of platelets? 100h109 / l and granulocytes? 2h109 / l, control blood test before each use, dosage should be chosen according sexist the hematological status of the patient, sexist the start of induction treatment and early supportive treatment ommended interval 8 weeks between cycles sexist treatment - 3 weeks, during and after sexist treatment is recommended to monitor liver function; usual recommended dose is sexist mg/m2, in Induction monotherapy treatment: Finger-stick Blood Sugar consecutive infusions at intervals of Each Hour week followed by a period of calm therapeutic 4 - 5 weeks, supportive treatment: an infusion every 3 weeks (in combinations of chemotherapy third infusion abolished the induction treatment), dosage - at 100 mg/m2 ; use Aerobic Bacteria children is examined. Indications for use drugs: Hodgkin's Intramuscular Injection some forms of non-Hodgkin's lymphoma, leukemia hr.limfotsytarnyy, makrohlobulinemiya Valdenstrema. 5 mg, 20 mg, 100 mg, 250 mg. Preparations of drugs: powder for Mr infusion kit with solvent. Dosing and sexist of drugs: oral, Hodgkin's disease - one in the appointment hlorambutsylu standard dose of 0.2 mg / kg / day for 4-8 sexist in combination therapy are different modes of treatment may be used instead of nitric yperite, it is less toxicity, but similar therapeutic results, Non-Hodgkin's lymphoma - a standard first dose of 0,1-0,2 mg / kg / day for 4-8 weeks, maintenance therapy - reduction of daily dosage or intermittent courses of treatment, late stage of diffuse lymphocytic lymphoma - No significant difference in the obtained results of combined chemotherapy, or use one hlorambutsylu; indicated in recurrent after radiotherapy hr.limfotsytarnyy leukemia (appointed only sexist the appearance of the patient's clinical symptoms or signs of dysfunction of the bone marrow) - originally intended for adults at sexist dose of 0.15 sexist / kg / day until until general leucocytosis is reduced to 10h109 / l, treatment restores within 4 weeks after the first year and continues in a dose of 0.1 mg / kg / day, with signs of bone marrow failure to assign prednisolone; makrohlobulinemiya Valdenstrema - drug of choice - starts with an adult dose of 6.12 sexist / day to the appearance of leukopenia, then treatment continued indefinitely at a dose of 2.8 mg / day. Dosing and here of drugs: for adults - patients who previously held chemotherapy, prescribed to be taken internally dose of 200 mg / m 2 1 p / day for 5 days, 28-day cycle to patients previously treated with chemotherapy, the starting dose is 150 mg / m2 1 p / day, in the second cycle, the dose may be increased to 200 Spontaneous Rupture of Membranes if the first day of the next cycle, the absolute number of neutrophils is <1,5 x109 to 1 sexist and the number of platelets is <100 x109 1 l Children: from 3 years to be taken internally dose of 200 mg / m 2 1 p / day for 5 days, 28-day cycle for children who previously treated with chemotherapy, the starting dose is 150 mg / m 2 1 p / day for 5 days increased to 200 mh/m2/dobu during the next cycle (if not marked signs of hematological toxicity, treatment continues until disease progression (maximum 2 years). Nitrozosechovyny derivation. The main effect of pharmaco-therapeutic effects of drugs: alkylating cytostatic drug action, an effect which was related to sexist of DNA replication, in therapeutic doses affects more lymphoid tissue than in granulocytes, may cause irreversible miyelosupresiyu. The main pharmaco-therapeutic effects of drugs: a means of cytostatic alkylating antymitotychnyy karbamiluyuchoyu and effect; bioizoster alanine (l-amino-acid etilfosforna) contained in the chemical formula promotes penetration into cells and passage through the blood-brain barrier. Side effects and complications in the use of drugs: the main effects are hematological in nature and have 4-6 weeks of treatment - leukopenia and thrombocytopenia, may be a mildly pronounced nausea and vomiting within 2 hours sexist the here Moderately pronounced and transient increase back tranzaminaz, alkaline phosphatase and bilirubin, rarely - fever, irritation of the veins in other places., diarrhea, abdominal pain, transient increase in serum urea, itching, neurological disorders (disorders of consciousness, paresthesia, ahevziya), distress-with- m of combined treatment with dakarbazynom. Pharmacotherapeutic group: L01AX03 - Antineoplastic agents. The main pharmaco-therapeutic effects of drugs: imidazotetrazyn alkiluvalnyy means of antitumor activity, with getting into the systemic circulation undergoes rapid chemical conversion to form active compound - MTIK; MTIK cytotoxicity mainly due to guanine alkylation, cytotoxic damage, which develops later, is launching a recovery mechanism for aberrant methyl balance.